Andersen Tax & Legal Adds Location in Querétaro, Mexico

SAN FRANCISCO-Wednesday, August 30th 2017 [ AETOS Wire ]
(BUSINESS WIRE)-- Andersen Global is proud to announce a new presence through the expansion of Andersen Tax & Legal in Mexico to Querétaro, an industrial city located north of Mexico City. Andersen Tax & Legal in Mexico now has offices in three locations in Mexico, including Mexico City and Guadalajara. Andersen Tax & Legal in Mexico became a member firm of Andersen Global in June of 2015.
“We are excited about the addition of Miguel Trejo as the lead Partner in Querétaro,” said José Luis Montes, Office Managing Partner of Andersen Tax & Legal in Mexico. “Miguel has deep expertise in transfer pricing, international tax, and financial accounting. The addition of the team in Querétaro further strengthens our capabilities within the region and ensures we are able to serve clients in a seamless way across the globe.”
Miguel remarked, “We are enthusiastic about the new location and the opportunities it presents. The location in Querétaro will allow us to provide a more comprehensive range of international services to our clients, and we are planning on continuing our growth in the near future.”
As one of the fastest growing states in Mexico, Querétaro is a significant location because of its industry and influx of businesses. The team in Querétaro specializes in transfer pricing and will expand its focus to include customs and international trade. Andersen Tax & Legal in Mexico will continue to provide deep tax expertise across many service lines, including international taxation, transfer pricing, corporate taxation and foreign trade.
“The addition of the location in Querétaro is indicative of the success of our team in Mexico and our growing capabilities within the region,” noted Mark Vorsatz, CEO of Andersen Tax in the U.S. “We are poised for significant growth in Latin America in the future.”
Andersen Global has a presence in 70 locations worldwide through its member firms and collaborating firms.
Contacts
Andersen Tax
Megan Tsuei, 415-764-2700




Permalink : http://aetoswire.com/news/4444/en

Study Evaluates Utility of Masimo SpHb® During High-Blood-Loss Oncosurgery

NEUCHATEL, Switzerland-Monday, August 28th 2017 [ AETOS Wire ]

(BUSINESS WIRE)-- Masimo (NASDAQ:MASI) announced today the findings of a recently published study in which researchers in New Delhi, India evaluated the utility of Masimo SpHb®, noninvasive, continuous hemoglobin measurement, during oncosurgery on patients with high anticipated blood loss.1

In the study, Dr. Gupta and colleagues sought to evaluate the utility of SpHb measurements on patients undergoing oncosurgery because oncosurgeries “may be associated with large blood loss, requiring repeated haemoglobin estimation for deciding the need for intraoperative blood transfusion.” They enrolled 50 adult patients with anticipated blood loss of at least 20%. During surgery, the patients’ SpHb was continuously monitored using a Masimo Radical-7® Pulse CO-Oximeter®. The researchers obtained venous blood samples, which were analyzed using a Beckman Coulter analyzer (LabHb), at the following points: immediately after induction, when approximately 500 ml of blood loss was suspected, and just before reversal of the neuromuscular blockade.

A total of 137 paired (SpHb and LabHb) data points were recorded for final analysis, including 66 at which packed red blood cell transfusions were made. The accuracy of SpHb in comparison to LabHb was assessed using Bland-Altman analysis. The level of agreement between SpHb and LabHb for the 66 transfusion data points showed a 73% correlation (p < 0.001), bias of -0.313 g/dL with standard deviation of ± 1.06 g/dL, and limits of agreement of -2.44 g/dL and 1.81 g/dL. The level of agreement between SpHb and LabHb for all 137 data points showed a 72.7% correlation (p < 0.001), bias of -0.376 g/dL with standard deviation of ± 1.27 g/dL, and limits of agreement of -2.92 g/dL and 2.16 g/dL.

The researchers concluded that, “Continuous SpHb monitoring can aid us regarding early blood transfusion decisions in oncosurgical patients along with other measures such as clinical judgement by attending consultant and haemodynamic variables. It may improve the intraoperative management of oncosurgeries by helping in real time and continuous decision-making for blood transfusion.” They also noted that SpHb “allows the physician to focus on the haemoglobin trend and detect either a slow decrease or a significant rapid drop in haemoglobin and therefore decide the appropriate time to perform an invasive measurement of haemoglobin.”

As limitations, the researchers stated that they “collected venous blood sample from central venous line rather [than] arterial blood. Haemoglobin concentration has been reported to be higher in venous blood than arterial blood though precision for haemoglobin estimation is higher for venous blood.” In addition, they suggested that further research may be needed to assess the effect of colloid administration and skin temperature at the probe site on SpHb accuracy, as well as its accuracy on patients with blood loss rates differing from the “massive but steady” rates observed in this study.

SpHb monitoring is not intended to replace laboratory blood testing. Blood samples should be analyzed by laboratory instruments prior to clinical decision making.

@MasimoInnovates | #Masimo

Reference

    Gupta N, Kulkami A, Bhargava AK, Prakash A, and Gupta N. Utility of noninvasive haemoglobin monitoring in oncosurgery patients. Indian Jour Anesth. July 2017; Volume 61; Issue 7; 543-548.

About Masimo

Masimo (NASDAQ:MASI) is a global leader in innovative noninvasive monitoring technologies. Our mission is to improve patient outcomes and reduce the cost of care. In 1995, the company debuted Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, which has been shown in multiple studies to significantly reduce false alarms and accurately monitor for true alarms. Masimo SET® has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates,1 improve CCHD screening in newborns,2 and, when used for continuous monitoring with Masimo Patient SafetyNet™* in post-surgical wards, reduce rapid response activations and costs.3,4,5 Masimo SET® is estimated to be used on more than 100 million patients in leading hospitals and other healthcare settings around the world,6 and is the primary pulse oximetry at 16 of the top 20 hospitals listed in the 2017-18 U.S. News and World Report Best Hospitals Honor Roll.7 In 2005, Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), Pleth Variability Index (PVi®), and more recently, Oxygen Reserve Index™ (ORi™), in addition to SpO2, pulse rate, and perfusion index (Pi). In 2014, Masimo introduced Root®, an intuitive patient monitoring and connectivity platform with the Masimo Open Connect™ (MOC-9™) interface, enabling other companies to augment Root with new features and measurement capabilities. Masimo is also taking an active leadership role in mHealth with products such as the Radius-7™ wearable patient monitor, iSpO2® pulse oximeter for smartphones, and the MightySat™ fingertip pulse oximeter. Additional information about Masimo and its products may be found at www.masimo.com. Published clinical studies on Masimo products can be found at http://www.masimo.com/cpub/clinical-evidence.htm.

ORi has not received FDA 510(k) clearance and is not available for sale in the United States.

*The use of the trademark Patient SafetyNet is under license from University HealthSystem Consortium.

References

    Castillo A et al. Prevention of Retinopathy of Prematurity in Preterm Infants through Changes in Clinical Practice and SpO2 Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
    de-Wahl Granelli A et al. Impact of pulse oximetry screening on the detection of duct dependent congenital heart disease: a Swedish prospective screening study in 39,821 newborns. BMJ. 2009;338.
    Taenzer AH et al. Impact of Pulse Oximetry Surveillance on Rescue Events and Intensive Care Unit Transfers: A Before-And-After Concurrence Study. Anesthesiology. 2010; 112(2):282-287.
    Taenzer AH et al. Postoperative Monitoring – The Dartmouth Experience. Anesthesia Patient Safety Foundation Newsletter. Spring-Summer 2012.
    McGrath SP et al. Surveillance Monitoring Management for General Care Units: Strategy, Design, and Implementation. The Joint Commission Journal on Quality and Patient Safety. 2016 Jul;42(7):293-302.
    Estimate: Masimo data on file.
    http://health.usnews.com/health-care/best-hospitals/articles/best-hospitals-honor-roll-and-overview.

Forward-Looking Statements

This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, among others, statements regarding the potential effectiveness of Masimo SpHb®. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of clinical results; risks related to our belief that Masimo's unique noninvasive measurement technologies, including Masimo SpHb, contribute to positive clinical outcomes and patient safety; risks related to our belief that Masimo noninvasive medical breakthroughs provide cost-effective solutions and unique advantages; as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.

Contacts

Masimo
Evan Lamb, 949-396-3376
elamb@masimo.com

Fordham Law to Host 44th Annual Conference on International Antitrust Law and Policy

 Speakers from Federal Trade Commission, Department of Justice, and EU Commission



NEW YORK-Tuesday, August 29th 2017 [ AETOS Wire ]

(BUSINESS WIRE)-- Fordham Law School’s 44th Annual International Antitrust Law and Policy Conference in New York City, led for the third year by Fordham Competition Law Institute Director James Keyte, will take place Thursday-Friday, 14-15 September 2017. The conference will feature topics focused the role of the courts in antitrust enforcement, “must-have” content and the antitrust playing field in media and sports, and the multijurisdictional challenge of e-commerce and antitrust.

Keynote speakers include Andrew Finch of the U.S. Department of Justice, Johannes Laitenberger of the EU Commission, Andreas Mundt of the International Competition Network Steering Group, and Maureen Ohlhausen of the U.S. Federal Trade Commission.

Additional speakers include antitrust agency heads Isabelle de Silva of France, John Pecman of Canada, Giovanni Pitruzzella of Italy, Han Li Toh of Singapore, and Pablo Trevisan of Argentina; judges Anthony Collins of the General Court of the European Union, Wenlian Ding of the Shanghai People's Court, and Amit Mehta of the U.S. District Court for the District of Columbia; and in-house counsel Horacio Gutierrez of Spotify, Mathew Heim of Qualcomm, Dina Kallay of Ericsson, Munesh Mahtani of Google, Greg McCurdy of Uber, and Greg Slater of Intel.

The institute has also organized two pre-conference events on 13 September.

• The Antitrust Economics Workshop will explore key topics for practitioners related to platforms, parity and pricing for digital markets; state-of-the-art economic analysis of mergers; and current trends in merger enforcement policy. In addition, Keyte will moderate a conversation with Nobel Laureate Daniel McFadden.

• The new Global Practitioners Workshop, conducted under the Chatham House Rule, will present two sessions on practical issues: protectionism and national interest in merger enforcement moderated by Cal Goldman of Goodmans LLP (Canada) and patent licensing in a multijurisdictional environment moderated by Ingrid Vandenborre of Skadden Arps (Brussels).

In-house counsel and newly admitted attorneys may register for free. Discounted registration is available for government attorneys and academics.

EVENTS:





Antitrust Economics Workshop and Global Practitioners Workshop,
   

September 13, 2017
   




 

44th Annual Conference on International Antitrust Law and Policy


 

September 14–15, 2017
   



WHERE:
 

Fordham Law School, 150 West 62nd Street, New York NY 10023
   



WEB:
 

Details and Registration
   

law.fordham.edu/fcli

Contacts

Fordham Law School
Carrie Johnson, 212-636-7604
Assistant Dean, Communications and Events
cjohnson@fordham.edu


Permalink : http://aetoswire.com/news/4442/en 

Global Two-Way Radio Communications Provider Hytera Sues Motorola Solutions for Patent Infringement

Manufacturer of Professional Mobile Radio Solutions Files in U.S. District Court in Ohio, Claims Motorola Solutions Infringes Hytera's Patented Sound Adjustment Technology in Mobile Radio Handsets 

SHENZHEN, China-Tuesday, August 29th 2017 [ AETOS Wire ]
(BUSINESS WIRE)-- Shenzhen, China-based Hytera Communications Corporation Limited, the world's leading provider of innovative professional mobile radio (PMR) solutions, today filed a lawsuit against Chicago, Ill.-based Motorola Solutions, Inc. in federal district court in Cleveland, Ohio, charging that Motorola Solutions is infringing Hytera's U.S. Patent No. 9,183,846, which covers its industry-leading sound adjustment control technology.
Hytera's '846 patent is its inventive method for adjusting sound volume in response to background or ambient noise, allowing a radio operator to hear and speak over it. The device obtains the current level of ambient noise, receives an instruction, and adjusts sound output. If ambient noise is high, the volume adjustment is greater at higher (treble) frequencies. Hytera's complaint asserts that Motorola Solutions unlawfully misappropriates Hytera’s patented technology for sound adjustment, incorporating it into its MOTOTRBO portable radios.
"Hytera has changed the landscape of the PMR business with its constant innovations, especially after its launch of a digital product line in 2010," said Tom Wineland, Director of Sales for Hytera Communications America (West), Inc. in Irvine, Calif. "Our patented sound adjustment functionality is one of the many innovations that Hytera has incorporated into our digital products, and users in markets around the world have embraced this feature."
Hytera's two-way radio communications equipment includes hand portables, mobiles, base stations, and dispatching and management software. Its products and solutions are used by commercial industries, such as energy companies and utilities, event organizers and producers, security and emergency management response teams, schools and other educational institutions, and public safety organizations. During use, personnel using Hytera's devices frequently move from quiet environments with little background noise to loud environments where machinery, engines, crowd noise, sirens, or other noises make it difficult to hear.
As embodied in the '846 patent, Hytera's sound adjustment capability is a key technological advance in PMR speaker design that is critical in a variety of noisy situations. "Our users—police and emergency responders, stadium and event managers, and commercial users—benefit greatly from this capability in our devices," adds Wineland.
"Motorola Solutions is infringing Hytera's sound adjustment control patent," said Andrew Yuan, Hytera's President of North and South America. "Hytera is a leader in innovative technologies, and an adamant advocate of intellectual property rights. We will look to enforce our patents in court in the U.S. and worldwide."
Hytera invests up to 15 percent of annual revenue in research and development, notes Yuan, including in open standard technologies, and is continually developing customized solutions that couple versatile LTE broadband for video and data transmission with traditional PMR narrow-band two-way voice communications. Hytera is one of the few companies worldwide that offers market-leading TETRA, DMR, and PDT technologies, and that offers products and solutions under all mainstream digital protocols. Hytera currently holds 480 issued patents, including 269 patents for digital products (DMR, TETRA, and PDT).
Hytera is the second-largest professional mobile radio communications solutions provider in the world, and the world’s fastest-growing. Hytera also is the world’s #1 DMR trunking provider. Hytera has partnered with companies in the U.S. since 2000, and established its first U.S. subsidiary, Hytera America, Inc., in 2004. Hytera established Hytera Communications America (West), Inc., in 2016 and opened research and equipment servicing facilities in the Chicago area this year.
Hytera further claims that Motorola has been and still is indirectly infringing Hytera's ‘846 Patent by actively inducing direct infringement by other persons who use products that embody one or more of the claims of the patent while Motorola had knowledge of the patent, knew or should have known that its actions would induce direct infringement by others, and intended that its actions would induce such direct infringement. Hytera is also alleging contributory infringement. Hytera is seeking damages and will pursue further relief as appropriate.
Hytera filed its lawsuit in the U.S. District Court for the Northern District of Ohio, in Cleveland, Ohio. The patent-at-issue is U.S. Patent No. 9,183,846 (“the ‘846 Patent”) titled “Method and Device for Adaptively Adjusting Sound Effect.” Hytera is represented in this action by Todd Tucker of Cleveland, Ohio-based law firm Calfee, Halter & Griswold LLP.
About Hytera Communications Corporation Limited
Founded in Shenzhen, China in 1993, Hytera Communications Corporation Limited is a closely-held privately-run company listed on the Shenzhen Stock Exchange (002583.SZ). With ten research and development centers around the world, Hytera is a leading global provider of innovative professional mobile radio (PMR) communications solutions to governmental organizations, public security institutions, and customers from other industries including transportation, oil and gas, and many others. Hytera aspires to leverage its technologies to improve organizational efficiency and make the world safer. Hytera's headquarters are at Hytera Tower, Shenzhen Hi-Tech Industrial Park North, Beihuan RD. 9108 Nanshan District, Shenzhen, P.R.C. In the U.S., the company has operations in Miramar, Fla., Irvine, Calif., and Chicago, Ill. More information is at www.hytera.com.

---

Contacts
Hytera Communications Corporation Limited
Johnny Jian
johnny.jian@hytera.com

Permalink : http://www.aetoswire.com/news/4439/en

 

20th Century Fox, Panasonic and Samsung Forge New Partnership to Deliver the Best Possible Viewing Experience with HDR10+ Technology

BERLIN-Tuesday, August 29th 2017 [ AETOS Wire ]

(BUSINESS WIRE)-- 20th Century Fox, Panasonic Corporation and Samsung Electronics announced today a new partnership to create an open, royalty-free dynamic metadata platform for High Dynamic Range (HDR) through an associated certification and logo program, tentatively called HDR10+. Together, the three companies will form a licensing entity that will begin licensing the HDR10+ platform in January 2018. The entity will license the metadata broadly to content companies, ultra-high definition TVs, Blu-ray disc players/recorders and set-top box manufacturers, as well as SoC vendors, royalty-free with only a nominal administrative fee.

“As leaders in home entertainment content and hardware, the three companies are ideal partners for bringing HDR10+ into the homes of consumers everywhere,” said Jongsuk Chu, Senior Vice President of the Visual Display Business at Samsung Electronics. “We are committed to making the latest technology available in our TVs and are confident that HDR10+ will deliver premium quality content and enhance the way you experience television programs and movies in the home.”

HDR10+ is a cutting-edge technology, building upon the benefits of HDR televisions, which offers the best possible viewing experience for next generation displays. HDR10+ provides unprecedented picture quality on all displays with brightness, color, and contrast automatically optimized for each scene. In previous iterations, static tone mapping applied a fixed enhancement across an entire piece of content. With HDR10+ dynamic tone mapping, every scene is individually enhanced to bring to life vibrant visuals and achieve unprecedented picture quality. This new enhanced visual experience will allow consumers to see pictures that match the intention of filmmakers.

“HDR10+ is a technological step forward that optimizes picture quality for next generation displays,” said Danny Kaye, Executive Vice President at 20th Century Fox and Managing Director of the Fox Innovation Lab. “HDR10+ provides dynamic metadata, which precisely describes every scene to deliver unprecedented picture quality. Working in partnership with Panasonic and Samsung through the Fox Innovation Lab, we are able to bring new platforms like HDR10+ to the market that more accurately realize the vision of our filmmakers beyond the theater.”

There are several key benefits for partners who wish to adopt the platform for their HDR10+ compliant products. HDR10+ offers system flexibility, allowing a variety of partners, including content creators, content distributors, TV manufacturers and device makers, to incorporate this platform and improve the viewing experience for audiences. The HDR10+ platform was designed to allow for future development and innovation in order to deliver a more powerful technology in the years to come.

“Panasonic has a long history of working with industry leaders to develop lasting technical formats. We are delighted to work together with 20th Century Fox and Samsung to develop a new HDR format, which will bring consumers so many benefits,” said Yuki Kusumi, Executive Officer at Panasonic. “By offering considerable HDR picture quality improvements across a wider range of TVs while accelerating the amount of premium HDR content available, we expect HDR10+ to quickly become the defacto HDR format.”

This year’s IFA attendees are encouraged to visit the Samsung Electronics and Panasonic booths to learn more about HDR10+ technology.

20th Century Fox, Panasonic and Samsung will announce further details on the license program along with a demonstration of HDR10+ technology at CES 2018.

About Twentieth Century Fox Home Entertainment
Twentieth Century Fox Home Entertainment, LLC (TCFHE) is a recognized global industry leader and a subsidiary of Twentieth Century Fox Film. TCFHE is the worldwide marketing, sales and distribution company for all Fox film and television programming, acquisitions and original productions as well as all third party distribution partners on DVD, Blu-ray™, 4K Ultra HD, Digital HD, and VOD (video-on-demand). Each year TCFHE introduces hundreds of new and newly enhanced products, which it services to retail outlets and digital stores throughout the world.

About Panasonic
Panasonic Corporation is a worldwide leader in the development of diverse electronics technologies and solutions for customers in the consumer electronics, housing, automotive, and B2B businesses. Celebrating its 100th anniversary in 2018, the company has expanded globally and now operates 495 subsidiaries and 91 associated companies worldwide, recording consolidated net sales of 7.343 trillion yen for the year ended March 31, 2017. Committed to pursuing new value through innovation across divisional lines, the company uses its technologies to create a better life and a better world for its customers. To learn more about Panasonic: http://www.panasonic.com/global.

About Samsung Electronics Co., Ltd.
Samsung inspires the world and shapes the future with transformative ideas and technologies. The company is redefining the worlds of TVs, smartphones, wearable devices, tablets, digital appliances, network systems, and memory, system LSI and LED solutions. For the latest news, please visit the Samsung Newsroom at http://news.samsung.com.

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=51674628&lang=en



Contacts

April Carreta
20th Century Fox
Tel: +1-310-369-5827
april.carretta@fox.com
or
Global Communications Department
Panasonic Corporation
Tel: +81-(0)3-3574-5664
http://news.panasonic.com/global/contacts/
or
Dahhee Chung
Samsung Electronics Co., Ltd.
Tel: +82-10-3816-8146
Dahee.chung@samsung.com



Permalink : http://aetoswire.com/news/4440/en

Nordson EFD Shares Benchtop Fluid Dispensing Best Practices in New Video Series

 Videos help manufacturers improve process control when dispensing assembly fluids with air-powered benchtop dispensers



EAST PROVIDENCE, R.I.-Thursday, August 24th 2017 [ AETOS Wire ]

(BUSINESS WIRE)-- Nordson EFD, a Nordson company (NASDAQ: NDSN) and the world’s leading manufacturer of precision fluid dispensing systems, introduces a new Better Dispensing™ How-To Video series. These three short but highly-educational videos, hosted by EFD Application Specialist Tom Muccino, provide best practices for setting up and troubleshooting benchtop fluid dispensers.

“Sometimes it’s the little things ─ such as making sure there are no contaminants in your plant air supply or that you’re always dispensing in Timed mode ─ that can improve production throughput by applying fluid in a more accurate, repeatable way,” Muccino said. “These videos aim to share often-overlooked best practices that can improve the performance of your dispenser and provide significant cost and time savings in the long run.”

Nordson EFD manufactures an Ultimus™ series and a Performus™ series of pneumatic dispensers, also known as air-powered dispensers. This video series focuses on best practices.

    The first video outlines the importance of plant air supply in maximizing the productivity and accuracy of a precision fluid dispenser.
    The second video shows manufacturers how to setup a dispenser to apply the right amount of fluid consistently to improve throughput and achieve higher part quality.
    The third video provides practical steps to take when a dispenser appears to not be working. Often the solution is as simple as making sure the adapter assembly safety clip is unclipped.

These new Better Dispensing How-To Videos are the second series of educational videos from Nordson EFD. The goal is to provide best practices to help manufacturers improve dispensing processes to achieve greater throughput while reducing rejects, rework, and fluid waste. Visit nordsonefd.com/HowTo to watch future installments.

For more information, email Nordson EFD at info@nordsonefd.com, or call +1 401.431.7000 or 800.556.3484.

About Nordson EFD

Nordson EFD designs and manufactures precision fluid dispensing systems for benchtop assembly processes and automated assembly lines. By enabling manufacturers to apply the same amount of adhesive, lubricant or other assembly fluid to every part, every time, EFD dispensing systems are helping companies in a wide variety of industries increase throughput, improve quality, and lower their production costs. Other fluid management capabilities include high-quality syringe barrels and cartridges for packaging one- and two-component materials, along with a wide variety of fittings, couplers and connectors for controlling fluid flow in medical, biopharmaceutical and industrial environments. The company is also a leading formulator of specialty solder pastes for dispensing and printing applications in the electronics industry.

About Nordson Corporation

Nordson engineers, manufactures, and markets differentiated products and systems used for dispensing and processing adhesives, coatings, polymers, sealants and biomaterials; and for managing fluids, testing and inspecting for quality, treating surfaces and curing. These products are supported with extensive application expertise and direct global sales and service. We serve a wide variety of consumer non-durable, consumer durable and technology end markets including packaging, nonwovens, electronics, medical, appliances, energy, transportation, building and construction, and general product assembly and finishing. Founded in 1954 and headquartered in Westlake, Ohio, the company has operations and support offices in more than 30 countries. Visit Nordson on the web at nordson.com, twitter.com/Nordson_Corp or facebook.com/nordson.

Contacts

Nordson EFD
Natalie Tomasso, +1-401-431-7173 (USA)
Marketing Communications Specialist
natalie.tomasso@nordsonefd.com
or
Nordson EFD
Global
Natalie Tomasso, +1-401-431-7173
natalie.tomasso@nordsonefd.com
or
Europe
+44 (0) 1582 666334
europe@nordsonefd.com
or
China
+86 (21) 3866 9006
china@nordsonefd.com
or
Japan
+81 (03) 5762 2760
japan@nordsonefd.com
or
SEAsia
+65 6796 9522
sin-mal@nordsonefd.com
or
India
+91 80 4021 3600
india@nordsonefd.com

Permalink : http://www.aetoswire.com/news/4420/en

World Innovations Forum Launching in Lucerne, Switzerland

New movement, enabling a global exchange for innovative minds, doubling entrepreneurial success, increasing prosperity equality



LUCERNE, Switzerland-Tuesday, August 29th 2017 [ AETOS Wire ]

(BUSINESS WIRE)-- Approximately 1,200 innovation stakeholders from 50 countries, including entrepreneurs, investors, incubators, accelerators, mentors, and economic development officers expect to join forces for the first time, solving the most burning challenges of entrepreneurship. The World Innovations Forum takes place in Lucerne, Switzerland, June 6 to 8 2018. Doubling entrepreneurial success rate by 2035, creating more equality for prosperity is the main objective. “Our mindset is on global prosperity equality,” said Axel Schultze, co-founder and board member of the WIForum.

Conference topics are reported in advance and include: fundraising, mentorship, taxation, legal barriers, lack of ecosystems, lack of entrepreneurial mindset, societal issues and more. The main objective is to define immediate actions, stopping the so-called brain drain, where young entrepreneurs move to other countries, reducing the ability of their country’s innovation development.

Carol Ackermann, a founding member about the difference to other conferences: “From listening to exploring and making – a truly global initiative with the mutual understanding: 'the more you put in the more you get out.'” Only a few, but very igniting keynote speakers will inspire this forum.

Participating countries are organizing monthly “national startup competitions.” The winners from each country will be invited to Lucerne in 2018 and compete for the world’s best startup. The organization will help several hundred innovative entrepreneurs to gain global visibility at no cost to the startups.

“We don’t want to be an elite club, but make sure the most qualified people join the forum,” said Rene Zeier, co-founder and CEO of the WIForum. Attendance is either by invitation or confirmed application only.

For businesses from any country to equally represent themselves in the WIForum, sponsorship levels are based on gross domestic product per capita (GDP/C). A lead sponsor from Rwanda would pay €750 while the same sponsor level from a French business would be asked to pay €38,000.

Khem Lakai, WIForum ambassador from Nepal: “Challenges we face in Nepal may be different from Nigeria, France, or Japan and never in our history the world comes together to this scale to share, and solve entrepreneurial problems of today and tomorrow.”

World Innovations Forum was founded by a group of entrepreneurs and investors from multiple countries. More information http://wiforum.com

Contacts

World Innovations Forum
Manuela Rantra, +41 78 865 3992
manuela@wiforum.com
http://wiforum.com/media

Julphar’s Board of Directors appoints Jerome Carle as General Manager

Ras Al Khaimah, United Arab Emirates -Sunday, August 27th 2017 [ AETOS Wire ]
The regional leading pharmaceutical company Julphar announced today that its Board of Directors has appointed Jerome Carle as General Manager – effective immediately.
The Board expressed confidence in Jerome’s aptitude and competence to make an immediate impact to the business, to lead the management team and to execute the company’s strategic objectives. The Julphar roadmap – Vision 2020 – will be a key pillar to drive Julphar to the top of the MENA markets.
Commenting on his appointment, General Manager Jerome Carle said: “I am very pleased, honored and humbled to have been appointed to this role, and I would like to thank the members of the Board for their trust. I am thrilled to serve a company that makes a real difference in patients and consumers’ quality of life. Julphar is uniquely positioned in the Middle East and African markets to improve the healthcare system and I am proud to play a role in achieving our company’s mission.”
Jerome Carle joined Julphar in January 2017 as Chief Financial Officer. He has over 20 years of financial expertise in emerging markets and his broad experience has shown his ability to deliver results in challenging environments. He has a proven track-record in the pharmaceutical industry, having served in the most reputable multi-national companies, with a full hand responsibility on the business operations, financials and administration.
About Julphar
Established in 1980, Julphar is one of the largest pharmaceutical manufacturers in Middle East and North Africa, producing over 200 branded products across 16 facilities. Julphar’s mission is to offer high quality medicines at affordable prices. Our product portfolio includes Biotechnology, Wound and Women Care, Adult and Pediatric General Medicines, Gastro and Pain Management, Cardio-Metabolism, Diabetes Solutions and Consumer range. Julphar employs more than 3,000 people around the world and registered revenue of AED 1.45 billion in 2016. For more information, please visit http://www.julphar.net.
Contacts
Julphar

Lama Mohanna, Communication Coordinator

M (+971-50)1740731, T (+971-7)2461461, D  (+971-7)2045722

lama.mohanna@julphar.net

Permalink : http://aetoswire.com/news/4433/en

Kenya’s Captains of Industries and Executives to Swing against HIV/AIDS at AHF Chairman’s Golf Tournament

NAIROBI, Kenya-Saturday, August 26th 2017 [ AETOS Wire ]
(BUSINESS WIRE)-- Today, Kenya’s captains of industries, government officials and executives will converge for the prestigious annual AIDS Healthcare Foundation (AHF) Kenya Chairman’s Golf Tournament at the Kiambu Golf Club in Nairobi.
This year, the tournament shall reach about 350 people with HIV/AIDS information and, as well provide HIV testing services to no less than 150 people.
Since inception in 2014, the AHF Chairman’s Golf Tournament has reached over 1,000 people with essential HIV/AIDS information and testing services.
The tournament strategically targets the nation’s captains of industries, senior government officials and other top business executives who are traditionally left out of HIV programming interventions.
AHF Kenya Chairman’s Golf Tournament honours Ambassador Dr. Stephen Karau, Chairman of the AHF Board of Trustees, who remains a major and active player in HIV/AIDS programming and in the public health sector in Kenya. Through the tournament, Ambassador Karau’s passion of impacting lives becomes projected once again, especially through bringing crucial HIV/AIDS services closer to an important but neglected group.
AHF is a non-profit Global NGO, legally registered in the US in 1987. The organization commenced its operations in Kenya in 2007 and was officially registered as an NGO in June 2008. Currently, AHF works in 9 counties, namely: Makueni, Mombasa, Nairobi, Turkana, Muranga, Nakuru, Kisii, Kilifi and Homabay County, supporting more than 120 health facilities and serving more than 38,000 patients.
AIDS Healthcare Foundation (AHF), the largest global AIDS organisation, currently provides medical care and services to over 805,000 individuals in 39 countries worldwide in the US, Africa, Latin America/Caribbean, the Asia/Pacific Region and Eastern Europe. To learn more about AHF, please visit our website: www.aidshealth.org, find us on Facebook: www.facebook.com/aidshealth and follow us on Twitter: @aidshealthcare and Instagram: @aidshealthcare
Contacts
AHF KENYA MEDIA CONTACT
Faith Ndungu
Program Development and Advocacy Manager
faith.ndungu@aidshealth.org
or
AHF AFRICA MEDIA CONTACT
Oluwakemi Gbadamosi
Senior Manager PR and Communications – Africa Bureau
Oluwakemi.gbadamosi@aidshealth.org

Permalink : http://aetoswire.com/news/4432/en

Celularity, Inc., Accelerates Breakthrough Placental Discovery & Therapeutic Platform

---New Biotechnology Company Accelerates the Delivery of Transformative Innovations in Treatments of Cancer, Inflammatory & Degenerative Diseases, and Functional Regeneration

---Contributions of Capital, More Than 200+ Issued and Pending Patents, Pre-Clinical and Clinical Assets and Commercial Products Obtained from Companies Including Celgene Corporation, Sorrento Therapeutics (Nasdaq: SRNE), United Therapeutics (Nasdaq: UTHR), and Human Longevity, Inc



WARREN, N.J.-Wednesday, August 23rd 2017 [ AETOS Wire ]

(BUSINESS WIRE)-- Celularity, Inc., a newly formed biotechnology company, today announced its acceleration of cell and tissue regenerative therapies to address unmet medical needs in cancer and chronic and degenerative disease. Celularity completed their Series A financing with contributions from several biopharma companies, including Sorrento Therapeutics, United Therapeutics Corporation and Human Longevity, Inc., and entrepreneurial investors.

Celularity has been created through the contributions of extensive intellectual property, clinical-stage assets, basic and clinical research, and development expertise including:

    Several clinical-stage immuno-oncology and regenerative medicine assets and a pipeline of pre-clinical assets
    Proprietary allogeneic (“readily accessible”) immunotherapy platform
    200+ issued and pending patents in cell therapy; robust IP for placental stem cells
    Broad fully human antibody-CAR constructs
    IND-ready joint CD38 immuno-oncology programs
    Commercial-stage functional regeneration products Biovance® and Interfyl®* and pipeline assets
    LifeBankUSA stem cell biorepository with two decades operating expertise

Founded on the pioneering work of Robert Hariri, MD, PhD, in human placenta-derived cellular therapeutics and biomaterials, Celularity’s ability to procure placental stem cells, engineer potential therapies, and deploy potential treatments, positions it to harness the potential of the human placenta and operate along the entire value chain.

“Celularity was formed as a new biotechnology model designed to apply the necessary expertise to harness our placenta discovery platform across a range of unmet medical needs,” said Celularity Founder and Chief Executive Officer, Robert J. Hariri, MD, PhD. “With the support of our investors, we are assembling proven regenerative medicine technology and expertise with the goal of developing transformative therapies for fatal and intractable diseases.” Dr. Hariri was previously chairman, chief scientific officer and chief executive officer of Celgene Cellular Therapeutics and founder of Anthrogenesis Corporation, which Celgene acquired in 2002. Dr. Hariri is also the co-founder of Human Longevity, Inc.

The formation of Celularity leverages seminal work in the discovery of novel biologically active cell populations in the human placenta with broad therapeutic potential. Celularity will draw upon these proprietary and scalable discoveries that derive from the post-partum human placenta – an ethical and renewable source of usable biomaterials. Celularity’s development program is focused on an allogeneic platform, leveraging clinically accessible, immune-tolerant cells and biomaterials from a diverse population of informed-consent donors.

Andrew von Eschenbach, MD, among the founding members of the Celularity Board of Directors and former United States Food and Drug Administration (FDA) Commissioner and Director of the National Cancer Institute said, “The pioneering work of Celularity founder Bob Hariri has unleashed the unique properties of placental derived stem cells which have renewed hope for creating safe and effective therapies for the most challenging degenerative diseases." Dr. von Eschenbach added "Celularity with its focus on accelerating innovation in regenerative medicine can become the leading catalyst for cell therapy to address many of the world's unmet medical needs."

*Interfyl is a registered trademark of Alliqua BioMedical, Inc.

Dr. Henry Ji, President and CEO of Sorrento Therapeutics, said, “We are very excited to participate in the creation of Celularity together with Dr. Hariri and his scientific team as well as global leading biopharmaceutical companies, such as Celgene, Human Longevity Inc., and United Therapeutics. The potential for regenerative therapies in treating a wide array of chronic degenerative conditions is well known. We see important synergies for the oncology field and the potential to enhance our fight against malignant cancers. Celularity’s technologies, assets, and resources will help advance selected Sorrento cellular therapy programs and potentially transform autologous cellular therapies into affordable and accessible allogeneic cell therapies.”

About Celularity, Inc.

Celularity, headquartered in Warren, New Jersey, is a biotechnology company with proprietary, leading-edge technology and Intellectual Property to harness the power of the placenta. Their medicine asset portfolio consists of more than 200 issued or pending patents as well as pre-clinical and clinical assets including CAR constructs for allogeneic CAR-T/NK products, licenses of 100+ immunotherapy assets, and commercial stage biosourcing and functional regeneration businesses. For more information, please visit www.celularity.com. Follow Celularity on Social Media: @Celularity.

About United Therapeutics

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of innovative products to address the unmet medical needs of patients with chronic and life-threatening conditions.

About Sorrento Therapeutics

Sorrento is an antibody-centric, clinical stage biopharmaceutical company developing new treatments for immuno-oncology, inflammation and autoimmune diseases. Sorrento's lead product candidates include immunotherapies focused on the treatment of both solid tumors and hematological malignancies, as well as late stage pain products. For more information, please visit http://sorrentotherapeutics.com

About Human Longevity, Inc.

Human Longevity, Inc. (HLI) is the genomics-based, health intelligence company creating the world’s largest and most comprehensive database of whole genome, phenotype and clinical data. HLI is developing and applying large scale computing and machine learning to make novel discoveries to revolutionize health. In addition to the HLIQ Whole Genome and HLIQ Oncology, HLI’s business also includes the HLI Health Nucleus, a genomic powered clinical research center which uses whole genome sequence analysis, advanced clinical imaging and innovative machine learning, along with curated personal health information, to deliver the most complete picture of individual health. For more information, please visit http://www.humanlongevity.com or http://www.healthnucleus.com

Contacts

Media:
For Celularity
Olivia Goodman, 212-715-1597
olivia.goodman@finnpartners.com
or
Sorrento Therapeutics, Inc.
Alexis Nahama, DVM, 858-203-4120
anahama@sorrentotherapeutics.com

Permalink : http://www.aetoswire.com/news/4415/en

Publication of Clinical Data Demonstrating Low Immunogenicity and Excellent Efficacy of Nuwiq® in Previously Untreated Patients

LACHEN, Switzerland-Thursday, August 24th 2017 [ AETOS Wire ]

(BUSINESS WIRE)-- Octapharma is delighted to announce the publication of interim data from the NuProtect study (GENA-05, NCT01712438), the first clinical data on treatment with Nuwiq® in previously untreated patients (PUPs), on August 16th 2017 as an Early View article in the internationally renowned medical journal Haemophilia.

The NuProtect study was initiated in March 2013 to investigate the immunogenicity, efficacy and safety of Nuwiq® in PUPs with severe haemophilia A, who are at the greatest risk of developing inhibitors. The ongoing study has enrolled 110 PUPs of any age or ethnicity who will receive Nuwiq® for up to 100 exposure days (EDs), making it one of the largest studies with a single FVIII product. Patients who previously received any FVIII concentrates or blood products containing FVIII are excluded from the study.

The recently published article describes interim results for 66 PUPs treated for at least 20 EDs, the time by which most inhibitors arise. The cumulative incidence (95% confidence interval) was 20.8% (10.7–31.0) for all inhibitors and 12.8% (4.5–21.2) for high-titre inhibitors. The study reported excellent efficacy of Nuwiq® in the prevention of bleeds, with median annual bleeding rates of 0 for spontaneous bleeds and 2.40 for all bleeds. Nuwiq® was also efficacious for the treatment of bleeds (92.4% of bleeds were controlled with one or two infusions) and as surgical prophylaxis (rated as “excellent” or “good” for 89% of surgical procedures). These interim results confirm the excellent haemostatic efficacy reported with Nuwiq® in previously treated patients.

Larisa Belyanskaya, Head of IBU Haematology, said: “We are very excited by the results of the NuProtect study and pleased that these interim data are now available as a publication in the specialist peer-reviewed journal Haemophilia. This is the first study to report data from PUPs treated with a rFVIII produced in a human cell line, and the results further differentiate Nuwiq® from other products on the market.”

Olaf Walter, Board Member at Octapharma, added that “These data demonstrate low immunogenicity of Nuwiq® in PUPs, the patient group at the greatest risk of inhibitor development, and confirm the excellent efficacy observed in previously treated patients. This publication is a further important step towards Octapharma’s goal of enabling patients with coagulation disorders to live a normal life.”

Octapharma would like to thank everyone involved in the study, in particular the patients and their families, without whom this research would not be possible.

About the NuProtect (GENA-05) study

The NuProtect clinical study (NCT01712438) is a phase 3, open-label, interventional clinical study being conducted across 38 centres, to evaluate at least 100 previously untreated patients (PUPs) with severe haemophilia A of all ages and ethnicities enrolled for study up to 100 exposure days (EDs) or 5 years maximum. Patients treated previously with any FVIII concentrates/blood products containing FVIII are excluded. The primary objective is to assess the immunogenicity of Nuwiq® by determining inhibitor activity using the Nijmegen-modified Bethesda assay at a central laboratory. Final data from the NuProtect study are expected to become available in 2019. More information on this trial is available at www.clinicaltrials.gov. An extension study (GENA-15, NCT01992549) will further evaluate the long-term immunogenicity, efficacy and safety of Nuwiq® in PUPs.

About Nuwiq®

Nuwiq® is a 4th generation rFVIII protein1, produced in a human cell line without chemical modification or fusion with any other protein2. Nuwiq® is cultured without additives of human or animal origin2, is devoid of antigenic non-human protein epitopes3 and has a mean half-life of 17.1 hours4,5 and a high affinity for the von Willebrand coagulation factor6. Nuwiq® treatment has been assessed in seven completed clinical trials which included 201 PTPs7,8 (190 individuals) with severe haemophilia A, including 59 children9. Nuwiq® is approved for use in the treatment and prophylaxis of bleeding across all age groups of PTPs with haemophilia A in the EU, US, Canada, Australia, Latin America and Russia. Further worldwide submissions for Nuwiq® are planned.

References:
1. FDA Nuwiq® memorandum (STN 125555), 9 October 2014.
2. Casademunt E, et al. Eur J Haematol 2012; 89: 165-76.
3. Kannicht C, et al. Thromb Res. 2013;131:78-88.
4. Nuwiq® European Public Assessment Report, 22 May 2014.
5. NUWIQ® US Prescribing Information, September 2015.
6. Sandberg H, et al. Thromb Res 2012; 130: 808-17.
7. Valentino LA, et al. Haemophilia 2014; 20(Suppl. 1): 1-9
8. Lissitchkov T, et al. Haemophilia 2017; e-pub ahead of print; doi: 10.1111/hae.13251
9. Klukowska A, et al. Haemophilia 2016; 22, 232-39.

About Haemophilia A

Haemophilia A is an X-linked hereditary disorder caused by FVIII deficiency which, if left untreated, leads to haemorrhages in muscles and joints and consequently to arthropathy and severe morbidity. FVIII replacement prophylactic treatment reduces the number of bleeding episodes and the risk of permanent joint damage. This disorder affects one in every 5,000 to 10,000 men worldwide. Globally, 75% of haemophilia cases are left undiagnosed or untreated. The development of neutralising FVIII antibodies (FVIII inhibitors) against infused FVIII represents the most serious treatment complication. The cumulative risk of FVIII inhibitor development is reported to be currently up to 39%.

About Octapharma

Headquartered in Lachen, Switzerland, Octapharma is one of the largest human protein manufacturers in the world, developing and producing human proteins from human plasma and human cell lines. As a family-owned company, Octapharma believes in investing to make a difference in people’s lives and has been doing so since 1983; because it’s in our blood.

In 2016, the Group achieved €1.6 billion in revenue, an operating income of €383 million and invested €249 million to ensure future prosperity. Octapharma employs more than 7,100 people worldwide to support the treatment of patients in 113 countries with products across three therapeutic areas:

    Haematology (coagulation disorders)
    Immunotherapy (immune disorders)
    Critical care

Octapharma owns six state-of-the-art production facilities in Austria, France, Germany, Mexico and Sweden.

For more information visit www.octapharma.com

Contacts

Octapharma AG
International Business Unit - Haematology
Olaf Walter
Olaf.Walter@octapharma.com
or
Larisa Belyanskaya
Larisa.Belyanskaya@octapharma.com
Tel: +41 55 4512121


Permalink : http://aetoswire.com/news/4418/en

Pradaxa® (dabigatran etexilate) dual therapy showed lower rates of major bleeding versus triple therapy with warfarin in atrial fibrillation patients undergoing stent placement

 ● RE-DUAL PCI™ showed large reductions in the incidence of bleeding complications if Pradaxa® dual therapy was used instead of warfarin triple therapy

● Both Pradaxa® doses tested in RE-DUAL PCI™ have been approved for stroke prevention in atrial fibrillation

● Data were presented as a late-breaker at the ESC Congress 20171 and published in the New England Journal of Medicine2



INGELHEIM, Germany-Sunday, August 27th 2017 [ AETOS Wire ]

(BUSINESS WIRE)-- The RE-DUAL PCI™ trial explored anticoagulation with Pradaxa® (dabigatran etexilate) dual therapy without aspirin in non-valvular atrial fibrillation (AF) patients following percutaneous coronary intervention (PCI) and stent placement: results showed significantly lower rates of major or clinically relevant non-major bleeding events for dual therapy with Pradaxa® when compared to triple therapy with warfarin.1,2 The risk for the primary safety endpoint was 48% lower for Pradaxa® 110 mg dual therapy and 28% lower for Pradaxa® 150 mg dual therapy (relative difference), with similar rates of overall thromboembolic events. Both Pradaxa® doses have been approved by regulatory authorities around the world for stroke prevention in AF. The results were presented today as a late-breaker at the ESC Congress 20171 and have been simultaneously published in the New England Journal of Medicine.2

Approximately 20–30% of patients with AF who are continuously taking an oral anticoagulant (OAC) to reduce their risk of AF-related stroke have coexisting coronary artery disease and may require a PCI using stent placement to improve blood flow to the heart.3 The combination of potent antithrombotic therapies associated with triple therapy with warfarin and two antiplatelets is associated with high rates of major bleeding in these patients.4-7 RE-DUAL PCI™ tested an alternative treatment strategy: dual therapy with Pradaxa® and a single antiplatelet, but without aspirin.

“For physicians treating patients with atrial fibrillation who have undergone percutaneous coronary intervention with stent placement, it is paramount to balance the efficacy required with the risk of bleeding,” said Christopher Cannon, MD, cardiologist at Brigham and Women’s Hospital, lead investigator of RE-DUAL PCI™, and executive director of the Cardiometabolic Trials at the Baim Institute for Clinical Research. “Previously we did not have a lot of dedicated data on non-vitamin K oral anticoagulants in this setting; the results from RE-DUAL PCI™ are relevant to fellow physicians who care for these types of patients and are looking for an effective antithrombotic treatment regimen.”

The results were:1,2

    Incidence of primary endpoint (time to major or clinically relevant non-major bleeding event):
        15.4% for Pradaxa® 110 mg dual therapy versus 26.9% for warfarin triple-therapy, which translates into a 48% lower risk
        20.2% for Pradaxa® 150 mg dual-therapy versus 25.7% for warfarin triple therapy, which translates into a 28% lower risk
    Both Pradaxa® dual therapy groups also showed lower rates of major bleeding (when analysed alone, both for the ISTH* and the TIMI** major bleeding definitions) and total bleeding
    Key secondary endpoint (combining death, myocardial infarction, stroke, systemic embolism and unplanned revascularisation):
        Similar rates of events were observed: 13.7% for the two Pradaxa® dual therapy groups combined, versus 13.4% for warfarin triple therapy

“The results we have seen from RE-DUAL PCI™ are another great piece of evidence on the benefit Pradaxa® can offer patients with atrial fibrillation and their treating physicians; a benefit which has been shown in many situations along the treatment journey,” commented Professor Jörg Kreuzer, Vice President Medicine, Therapeutic Area Cardiovascular, Boehringer Ingelheim. “Especially if you also take into account other recent data like the RE-CIRCUIT™ study in catheter ablation, evidence from ‘real-world studies’ or the results of the RE-VERSE AD™ study in emergency situations. Together, these data paint a really compelling picture of the safety and efficacy profile of Pradaxa.”1,2, 8-18

*ISTH, International Society on Thrombosis and Haemostasis

**TIMI, Thrombolysis In Myocardial Infarction

Please click on the link for ‘Notes to Editors’ and ‘References’: https://www.boehringer-ingelheim.com/RE-DUAL-PCI-ESC-2017

For more information, please visit: www.boehringer-ingelheim.com

Further Media Channels

www.facebook.com/boehringeringelheim

www.twitter.com/Boehringer

Contacts

Boehringer Ingelheim GmbH
Corporate Communications
Media + PR
Friederike Middeke
Phone: +49 6132 – 77 141575
Fax: +49 6132 – 77 6601
E-mail: press@boehringer-ingelheim.com

Permalink : http://aetoswire.com/news/4435/en

The Campaign for Tobacco-Free Kids Urges U.S. Authorities to Investigate British American Tobacco

WASHINGTON-Friday, August 25th 2017 [ AETOS Wire ]
(BUSINESS WIRE)-- Following new allegations about the conduct of British American Tobacco (BAT) in Africa – published today by The Guardian – the Campaign for Tobacco-Free Kids is urging the U.S. Department of Justice and the U.S. Securities and Exchange Commission to investigate BAT and its subsidiaries for possible violations of the anti-bribery and accounting provisions of the Foreign Corrupt Practices Act (FCPA). Tobacco-Free Kids requested the investigation in a letter today to the two government agencies.
British American Tobacco has faced mounting allegations that the company engaged in widespread bribery and corruption in Africa to gain advantage over competitors and stifle government efforts to curb smoking. Earlier this month, the U.K. Serious Fraud Office (SFO) formally launched an investigation of BAT on suspicions of corruption.
An investigative report published on August 18, 2017 by The Guardian revealed new allegations that, for years, BAT secretly and possibly illegally moved millions of U.S. dollars in cash across international borders into the war-torn Democratic Republic of Congo (DRC) allegedly to support the company’s tobacco leaf operations in that country. The new allegations indicate BAT’s operations included engaging with armed rebels involved in the long-standing DRC conflict in order to make secret cash drops used to pay for tobacco leaf from farmers in Auzi, an unmapped town BAT built in the 1950’s, according to The Guardian.
In addition to possible violations of the FCPA, The Guardian report raises questions about whether BAT’s conduct in moving U.S. dollars during the DRC conflict also violates federal anti-money laundering laws, especially as the U.S. has had sanctions in place against the DRC since 2006. The story also exposes BAT’s role in flooding South Sudan with its cheapest cigarette brands following years of war and operating around terrorist networks in Somalia to continue selling cigarettes in the country.
The growing allegations about BAT’s conduct are particularly alarming following the July 2017 merger of BAT and Reynolds American in the United States. The recent merger places BAT in a leading position in the U.S. market and, according to BAT, created the largest tobacco company in the world by operating profits.
“Given British American Tobacco’s decades-long history of calculated deception in the United States and abroad and its re-entry into the U.S. market, the mounting allegations of corruption and mass concealment of funds by BAT must be fully investigated by U.S. regulators for possible violations of the Foreign Corrupt Practices Act and any other applicable criminal or civil laws,” said Matthew L. Myers, President of the Campaign for Tobacco-Free Kids. “This is a company that has proven it cannot and will not play by the rules. Unless and until they are held accountable by governments, shareholders, business partners and the public, the company’s wrongdoing will only continue.”
Alleged corruption within BAT was first publicly exposed in November 2015 when the BBC, and later other news outlets, revealed allegations that the company was engaging in bribery and other corrupt acts that included bribing Ministry of Health officials in Burundi, Comoros and Rwanda, a former Kenyan Minister of Justice and a Member of Parliament from Uganda.
Tobacco use kills more than seven million people worldwide each year. Without urgent action by governments to pass proven tobacco control laws and curb the power and influence of tobacco companies, tobacco use will kill one billion people this century.
Contacts
Campaign for Tobacco-Free Kids
Jenna Mosley, + 1 202-296-5469
jmosley@tobaccofreekids.org

Permalink : http://aetoswire.com/news/4424/en

SHUAA Capital Initiates Procedures for Securities Business Egypt Re-entry

 ● Move underscores belief in the Egyptian market

● Plays to boost UAE-Egyptian mutual economic and trade interests and relations

● Intended to help stimulate the flow of foreign investments into Egypt




Dubai, United Arab Emirates-Monday, August 28th 2017 [ AETOS Wire ]

SHUAA Capital, the United Arab Emirates-based integrated financial services firm, announced that it has formally begun discussions with Egyptian regulators for reintroducing its securities business into the Egyptian market.

As a stepping stone, SHUAA Capital’s Board of Directors has set a clear mandate targeting the Egyptian market for the expansion of the firm’s brokerage services under its broader Capital Markets offering. The decision to restart brokerage operations in Egypt, which was voluntarily suspended previously as the region recovered from the 2008 global recession which impacted trading volumes, is a key component of the Group’s long-term growth strategy, and reflects the firm’s belief in the fundamentals of the Egyptian market and the depth of opportunities available. 

Fawad Tariq-Khan, General Manager of SHUAA Capital, explains: “SHUAA Capital believes there still exists significant untapped potential to serve clients eyeing the Egyptian market with our Securities business. Moreover, we have ambitious plans to extend our platforms further beyond our local jurisdictions, to allow clients both current and prospective, direct access to other markets through a single trading account, blended with a suite of increasingly comprehensive brokerage services. We look forward to relaunching operations soon, with the guidance of the Egyptian authorities and regulators.”

Once reinstated by the respective regulators, SHUAA Securities Egypt will form an important addition to SHUAA’s brokerage network by offering retail and high-net-worth clients from across the region access to the Egyptian capital markets.

Cautionary Statement Regarding Forward-Looking Information:

This document contains forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Forward-looking statements can be identified by words such as: "anticipate,"

"aspire," "intend," "plan," "goal," "objective," "seek," "believe," "project," "estimate," "expect," "forecast," "strategy," "target," "trend," "future," "likely," "may," "should," "will" and similar references to future periods.
Examples of forward-looking statements include, among others, statements we make regarding:

    Expected operating results, such as revenue growth and earnings.
    Anticipated levels of expenditures and uses of capital
    Current or future volatility in the capital and credit markets and future market conditions.

Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: Our ability to maintain adequate revenue levels and cost control; economic and financial conditions in the global markets and regional markets in which we operate, including volatility in interest rates, commodity and equity prices and the value of assets; the implementation of our strategic initiatives, including our ability to effectively manage the redeployment of our balance sheet and the expansion of our strategic businesses; the reliability of our risk management policies, procedures and methods; continued volatility in the capital or credit markets; geopolitical events; developments and changes in laws and regulations, including increased regulation of the financial services industry through legislative action and revised rules and standards applied by our regulators.

Any forward-looking statement made by us in this document and presentation is based only on information currently available to us and speaks only as of the date on which it is made. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. We undertake no obligation to publicly update any forward-looking statement whether as a result of new information, future developments or otherwise.

About SHUAA Capital psc

Established in 1979, SHUAA Capital psc (‘SHUAA’) is an integrated financial services firm headquartered in the United Arab Emirates. The firm services corporate and institutional clients, Governments, family businesses and high-net-worth-individuals with expertise in the areas of asset management, investment banking advisory services, capital markets and credit. SHUAA is a public shareholding company with its shares listed on the Dubai Financial Market. The firm is regulated as a financial investment company by the UAE Central Bank.  www.shuaa.com

Contacts

SHUAA Capital

Mohamed Tahboub

Head of Investor Relations, Corporate Communications & Marketing

+97143651872, mtahboub@shuaa.com / ccdesk@SHUAA.com

www.SHUAA.com


Permalink : http://aetoswire.com/news/4436/en

Easy Mobile Printing Reaches Every Android 8.0 Oreo User With Mopria Technology

Mopria Contributes Technology in Android 8.0 Oreo’s Default Print Service Providing Effortless Mobile Printing

SAN RAMON, Calif.-Saturday, August 26th 2017 [ AETOS Wire ]
(BUSINESS WIRE)-- The Mopria® Alliance, a global non-profit membership organization chartered to drive industry-wide standards and solutions for mobile printing, today announced it provided core printing technology to deliver intuitive mobile printing in the new Android 8.0 Oreo™ operating system. This contribution is the result of ongoing collaboration with the Google Android team via the Android Open Source Project and the Mopria Alliance.
Android 8.0 Oreo’s new Default Print Service features core technology from the Mopria Print Service, immediately delivering mobile printing convenience in the Operating System. With Mopria technology at the core of the Android 8.0 Oreo Default Print Service, users no longer need to download a mobile printing service and printer discovery is automatic, allowing easy mobile printing to more than 100 million Mopria certified printers from any Android 8.0 Oreo device.
“Mobile printing should be intuitive and ubiquitous, whether you’re at home, in the office, or on the go,” said Greg Kuziej, Chairman of the Board at the Mopria Alliance. “Thanks to Mopria technology, Google and the Android Open Source Project, we’re delivering easy mobile printing to Android users.”
Since its launch, the Mopria Print Service has enabled printing on Android (4.4 or later) smartphones and tablets to Mopria certified printers. Mopria allows users to easily print photos, web pages and documents when their mobile devices are connected to Mopria certified printers through a wireless network. Supported print settings include features such as color, number of copies, duplex, paper size, page print range, media type and orientation.
In the four years since the establishment of the Mopria Alliance by founders Canon, HP, Samsung and Xerox, the nonprofit membership organization has grown to 20 members representing the worldwide printer business. In addition to the founding companies, the Mopria Alliance today includes Adobe, Konica Minolta, Qualcomm, Lexmark, Kyocera, Toshiba, Brother, Epson, Fuji Xerox, NEC, Pantum, Ricoh, YSoft, Sharp, Dell and Primax.
While the Mopria Alliance will continue its efforts to make mobile printing easy, it will also expand its focus to standardizing cloud printing and scanning. Its goal is to make these solutions more accessible and intuitive for both consumer and business users.
Mopria certified printers make up 97% of printers sold worldwide. For the latest list of Mopria certified printers and print accessories, please visit http://mopria.org/certified-products.
About the Mopria® Alliance
The Mopria® Alliance is a non-profit membership organization of leading global technology companies with the initial goal of simplifying printing from smartphones, tablets and other devices. The Alliance develops and promotes technology standards that deliver an intuitive experience connecting different devices and mobile operating systems. The adoption of these standards allow users to seamlessly interact with a printer, regardless of brand. Plus, app downloads and setups for new mobile devices or printers will become unnecessary. Look for Mopria certified printers and accessories for easy printing with Mopria-enabled mobile devices. Learn more at www.mopria.org or download the latest Mopria software on the Google Play™ store.
Android is a trademark of Google Inc.
Contacts
Tech Image for Mopria Alliance
Harvey Henao, 312-673-6059
harvey.henao@techimage.com

Permalink : http://aetoswire.com/news/4429/en

Nominum and CIRA Create “Cyber-Secure Schools” Initiative to Bring Powerful Cyber Protections to Schools Throughout Canada

CIRA’s “Powered by Nominum” D-Zone DNS Firewall Protects Teachers, Students and Administrators from Ransomware and Other Malware through a Cost-effective, Easily Managed Cloud Solution


REDWOOD CITY, Calif.-Friday, August 25th 2017 [ AETOS Wire ]

(BUSINESS WIRE)-- Nominum™, an innovator of internet security solutions and services, and the Canadian Internet Registration Authority (CIRA), announced today that they have joined forces to deliver a powerful, cost-effective cloud security solution to K-12 schools, school boards and higher education institutions across Canada through a collaborative “Cyber-Secure Schools” initiative.

The Cyber-Secure Schools program aims to reduce malware risk, improve network performance and create safe online learning environments for teachers, students and administrators – as well as every device connected to the school network – through CIRA’s D-Zone DNS firewall powered by Nominum N2™ Secure Business.

Nominum and CIRA are already seeing rapid adoption of D-Zone by school boards across Canada, given the significant costs associated with cyberattacks, budget constraints, and the need for solutions that are easy to implement and manage. For example, the Wild Rose School Division in Rocky Mountain House, Alberta, has deployed the solution to protect its users from increasing incidents of ransomware and phishing attacks they see on their networks.

“Our district has a mobile-first strategy, driven by technology and learning strategies that are moving education beyond the classroom. Because of this, it’s critical that our network blocks malware and malicious content so students and teachers remain protected, no matter where they are,” said Jaymon Lefebvre, Director, IT Services for Wild Rose School Division. “This requires effective security that dynamically scales to meet growing demands and policy changes. The Nominum-CIRA Cyber-Secure Schools initiative and cloud security solution they provide ensures that the entire Wild Rose community is safeguarded from today’s dangerous threats.”

“Less than half of zero-day malware is detected by traditional anti-virus solutions, and since most malware uses DNS for command and control, our combined solution is an ideal first line of defense that complements any company’s security solution against emerging threats,” said Dave Chiswell, Vice President of Product Development for CIRA. “Through our partnership with Nominum we are delivering a better, more secure internet to schools and businesses throughout Canada, giving students, teachers and administrative staff assurances that educational activities taking place online are safe.”

Education Sector Hit Hardest by Ransomware, Driving the Need for Better Cybersecurity

U.S. government statistics show that the rate of ransomware attacks tripled in 2016 over 2015.1 Specifically, research conducted by the security ratings firm BitSight showed that ransomware strikes the education sector more than any other, with one in 10 schools having been hit with malware on their networks.2

“With cybercrime on the rise and schools facing budget and resource limitations, they are particularly vulnerable to cyberattacks that could cause long-term financial and operational damage,” said Arlen Frew, General Manager, Security Solutions for Nominum. “In today’s Digital Age, with more instruction and learning taking place online, it’s critical that schools have a powerful security infrastructure to keep students, teachers and other users protected. CIRA and Nominum are delivering enterprise-class security in a cost-effective solution that requires little hands-on maintenance – a combination that is missing from the education security marketplace.”

N2 Secure Business: Protecting SMBs in an Easily Managed Cloud Solution

Nominum N2 Secure Business is a ground-breaking cloud-based security solution that enables managed services providers like CIRA, as well as ISPs and telecom operators, to deliver a white-label security-as-a-service (SECaaS) solution to schools, government agencies and small and medium-sized business (SMB) customers. N2 Secure Business is quickly creating new revenue streams for these providers, which are now able to offer enterprise-class security in a solution that is ideally suited for the education sector from a cost and ease of management perspective.

The solution utilizes Nominum’s global DNS footprint and near real-time threat intelligence stream to discover and automatically block users from connecting to malicious domains and fills a critical market need for protection from ransomware, phishing and other malware in an easily managed solution that is suited to a small business budget. The technology also allows for simple management of content blocking, a requirement to ensure students in the K-12 environment are offered a safe and secure online experience.

N2-powered D-Zone DNS Firewall: The Ideal Hands-off Solution for K-12 and Higher Education Schools

The D-Zone DNS Firewall locates the technology in Canadian Internet Exchange Points to deliver a very high-performance recursive service, keep query data in Canada, help move more traffic onto low-cost, or free education and research networks and provide higher security. The Cyber-Secure Schools program further benefits schools by providing licensing models that recognizes the different user in a school board environment. And finally, schools (and businesses) can create, modify and grant different levels of access to content for students based on age-appropriate safe browsing polices.

About CIRA

The Canadian Internet Registration Authority (CIRA) manages the .CA top-level domain on behalf of all Canadians. CIRA also develops technologies and services that help support its goal of building a better online Canada. CIRA’s D-Zone Anycast DNS provides is the most comprehensive Canadian DNS solution available on the market, helping to improve security and performance for Canadian organizations. The CIRA team operates one of the fastest growing ccTLDs, a high-performance global DNS network, and one of the world’s most advanced back-end registry solutions. CIRA helps to support the Canadian Internet community through investments in Internet Exchange Points, the Canada Internet Forum, and the CIRA Community Investment Program.

About Nominum

Nominum™ is a pioneer and global leader in internet security and services innovation. The Silicon Valley company provides an integrated suite of carrier-grade DNS-based solutions that enable fixed and mobile operators, and managed services and web application providers to protect and enhance their networks, strengthen security for business and residential subscribers and offer innovative value-added services that can be monetized. The result is improved service agility, higher ARPU, increased brand loyalty and a strong competitive advantage. More than 130 service providers in over 40 countries trust Nominum to deliver a safe, customizable internet and promote greater value to over half a billion users. Nominum DNS software resolves 1.7 trillion queries around the globe every day—roughly 100 times more transactions than the combined daily volume of tweets, likes, and searches taking place on major web properties. For more information visit nominum.com.

Follow us on Twitter: @nominum https://twitter.com/nominum

Follow us on LinkedIn: https://www.linkedin.com/company/nominum

See us on YouTube: https://www.youtube.com/nominum

Read our latest Nominum blogs: http://nominum.com/blog/ | http://nominum.com/tech-blog/

1 https://malware.news/t/ransomware-attacks-increase-300-in-2016/10347

2 http://www.darkreading.com/attacks-breaches/education-now-suffers-the-most-ransomware-attacks-/d/d-id/1326960



Contacts

Nominum™
Nancy MacGregor, +1-415-309-5185
PR Director
nancy.macgregor@nominum.com

Permalink : http://aetoswire.com/news/4428/en

IBC2017 Hosts Charity Football Match in Aid of Local Charities

 - Match against ex-pro football legends forms part of 50th anniversary celebrations -



LONDON-Saturday, August 26th 2017 [ AETOS Wire ]

(BUSINESS WIRE)-- As part of IBC’s 50th anniversary celebrations, the organisation will host a charity football match on Saturday 16 September 2017 in aid of the Friendship Sports Centre and the Edwin van der Sar Foundation, two Amsterdam-based charities that provide support and rehabilitation through sporting activities for disadvantaged and disabled children and adults. IBC attendees are invited to donate to join the ‘IBC Legends’ squad, playing against a team of former Dutch professionals, The Lucky Ajax.

“Over the years the City of Amsterdam has become an integral part of the broadcast industry, and our 50th anniversary year seemed like a perfect opportunity to give something back to the local community. These charities provide support and rehabilitation and improve the lives of those faced with illness by giving them the opportunity to take part in activities that aren't usually available to them,” said Michael Crimp, CEO, IBC. “We are working with several of IBC’s friends and family to pull the event together, and have already seen some incredible generosity that will enable us to exceed our €25,000 target and help to support these excellent charities.”

The Friendship Sports Centre is a local charity supporting children and young adults with physical or mental disability or chronic illness by offering them somewhere where they can become part of a team through sporting activities. The Edwin van der Sar Foundation implements projects to support people with brain injuries through rehabilitation, participation and prevention. It is also a beneficiary of The Friendship Sports Centre.

Places on the team (subject to availability) require a €1500 donation for two players, allowing for a substitution. Those wishing to take part in the match, or interested in offering support in the form of sponsorship, should contact Nathalie Baker at nbaker@ibc.org. Donations can also be made directly on the IBC website or at the show - Look out for our volunteers and collection buckets.

The match will take place at The Friendship Sports Centre, Beemerstraat 652, Amsterdam 1027ED on Saturday 16 September from 18.00-21.30, with kick-off at 18:30. Entry for spectators is free and IBC will be providing free transfers to and from the venue, courtesy of its partner ITBholland. The buses will depart from Entrance C (Holland Entrance) at the RAI at 17:30, 18:00 and 18:30. A return service will be in place departing at 21:00, 21:30 and 22:00. Places on the buses will be allocated on a first come, first served basis.

About IBC

IBC is the world’s leading media, entertainment and technology show. It attracts 55,000+ attendees from more than 170 countries and combines a highly respected and peer-reviewed conference with an exhibition that showcases more than 1,700 leading suppliers of state of the art electronic media and entertainment technology.

IBC2017 Dates

Conference:





14 – 18 September 2017


Exhibition:
 

15 – 19 September 2017


For more information about IBC2017 visit: show.ibc.org/

Contacts

For further information, please contact:
Louise Wells, Bubble Communications for IBC
E: louisew@bubbleagency.com
T: +44 7718 985 252


Permalink : http://aetoswire.com/news/4431/en 

Saison Information Systems Switches Support for its SAP System to Rimini Street

 Leading Japan IT solutions company leverages savings from independent support to invest in new value-add services for customers



LAS VEGAS-Saturday, August 26th 2017 [ AETOS Wire ]

(BUSINESS WIRE)-- Rimini Street, Inc., a global provider of enterprise software products and services, and the leading independent support provider for Oracle and SAP products, today announced that Saison Information Systems (SISCO) has switched to Rimini Street support for its SAP ERP application. By switching to Rimini Street support, SISCO successfully optimized resources which are required to maintain and operate its SAP ERP system and, as a result, freed up resources to allocate for strategic initiatives that will deliver more value to their organization. SISCO’s business has been running their SAP system since 2006, and the company is now on release ECC 6.0.

“At the time of its introduction, we were completely satisfied with the functionality of our SAP system in terms of the automation of in-house mechanisms to carry out tasks, and found that it met our business needs perfectly," said Shuji Takahashi, director, Information Systems Department, SISCO. “On the other hand, we felt it was a huge disadvantage to keep paying costly fixed expenses for its maintenance and operation, even though it was running smoothly. We decided we needed to reallocate the resources required for the maintenance and operation of the ERP platform to focus instead on new value-add programs for the business, and this is what brought us to Rimini Street. Today, we enjoy premium-level support from our dedicated support engineer, and this gives us confidence to allocate resources towards other initiatives that will deliver more value to our organization, instead of spending resources on support of our system.”

All Rimini Street clients are assigned a dedicated local Primary Support Engineer (PSE) who is responsive to support requests 24/7/365. Rimini Street’s PSEs have an average of 15 years’ experience in the client’s specific ERP software. Clients also receive the Company’s industry-leading SLA, which guarantees a 15-minute response time for critical cases, and guaranteed maintenance for their current system for a minimum of 15 years without a required upgrade.

“As with many of our clients in Japan, Saison Information Systems is focused on maximizing the value of their significant investment in SAP software and optimizing the return on current IT expenditures,” said Yorio Wakisaka, general manager, North East Asia, Nihon Rimini Street. “We are pleased to help our many SAP clients in Japan, including SISCO, to cost-effectively run their current robust SAP releases for a minimum of 15 years, and allocate IT budget to more strategic initiatives that engage customers and drive competitive advantage. With Rimini Street’s proven, award-winning support, our clients can rest assured that their core ERP system is in good hands, so that they are freed up to focus on the more pressing, strategic aspects of their business.”

About Rimini Street, Inc.

Rimini Street is a global provider of enterprise software products and services, and the leading independent support provider for Oracle and SAP software products. The company has redefined enterprise support services since 2005 with an innovative, award-winning program that enables licensees of IBM, Microsoft, Oracle, SAP and other enterprise software vendors to save up to 90 percent on total support costs. Clients can remain on their current software release without any required upgrades for a minimum of 15 years. Over 1,330 global Fortune 500, midmarket, public sector and other organizations from a broad range of industries currently rely on Rimini Street as their trusted, independent support provider. To learn more, please visit http://www.riministreet.com follow @riministreet on Twitter and find Rimini Street on Facebook and LinkedIn.

Forward-Looking Statements

This press release may contain forward-looking statements. The words “believe,” “may,” “will,” “plan,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties, and are based on various assumptions. If the risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. Rimini Street assumes no obligation to update any forward-looking statements or information, which speak only as of the date of this press release.

© 2017 Rimini Street, Inc. All rights reserved. “Rimini Street” is a registered trademark of Rimini Street, Inc. in the United States and other countries, and Rimini Street, the Rimini Street logo, and combinations thereof, and other marks marked by TM are trademarks of Rimini Street, Inc. All other trademarks remain the property of their respective owners, and unless otherwise specified, Rimini Street claims no affiliation, endorsement, or association with any such trademark holder or other companies referenced herein.

Contacts

Rimini Street, Inc.
Michelle McGlocklin, +1 925-523-8414
mmcglocklin@riministreet.com

Permalink : http://aetoswire.com/news/4430/en

‘Celebrate Life’ at Sensation Dubai 2017

 Sensation returns to Dubai for just one night on 10th November and tickets are now on sale



Dubai, United Arab Emirates -Wednesday, August 23rd 2017 [ AETOS Wire ]

Sensation – returns to the City of Gold on November 10 and tickets are now on sale via platinumlist.net.  After three mesmerizing outdoor parties in Dubai, The World’s Leading Dance Event, is proud to announce its much-awaited return with a new show ‘CELEBRATE LIFE’ at Meydan on 10th November 2017.

Several ticket types, including hotel packages and Exclusive VIP tables, are on sale now, via platinumlist.net. You can choose to experience Sensation Dubai through a number of ways; all ticket descriptions and prices can be found online.

Sensation embarked on three beautiful journeys over the last three years when it all began with a deep experience at the “Source of Light”, then glided into the mesmerizing “Ocean of White” and most recently the experience where imaginations went wild at the “Desert Dome”. This year will be absolutely special as people unite together in white to pay their respects to the notions of love, unity and peace- this year we CELEBRATE LIFE!

Nicolas Vandenabeele, Director at Envie Events, says “We are happy to bring Sensation back to Meydan with a brand new show and ‘Celebrate Life’ together with thousands of like-minded party goers! As the most anticipated event of the year, we will push the boundaries of nightlife yet again to give music-lovers an exhilarating and inspiring spectacle.”

This ultimate nightlife experience, traveled across 5 continents, embraced 34 nations and united millions of people in white.  The all-white dress code creates the feeling of unity and works as a canvas for the show’s lights and effects which create a mind blowing effect on everyone’s imagination.

The last three editions were sold out with more than 14,000 people enjoying the ultimate nightlife experience. Watch this year’s ‘Celebrate Life’ trailer here:

 https://youtu.be/f9yfNxN4MDQ

More information on the show will be shared shortly.

Note to the Editor:

Date: Friday, 10th November, 2017

Venue: Meydan

Age Limit: Strictly 21+ years

Tickets are on sale now via PlatinumList.net:

https://dubai.platinumlist.net/event-tickets/59154/sensation-celebrate-life-dubai?show=74983

General admission tickets: Start from AED 340

Descriptions and prices of other ticket tiers and hotel packages can be found on Platinumlist.net

Download link for Sensation Dubai 2017 Trailer: https://we.tl/Nhuu0MTvG7

About Sensation

After three successful events, Sensation returns to Dubai for the fourth time. What began eighteen years ago as a one-off dance event in the Amsterdam Arena is now an international phenomenon. Until now, Sensation has toured 35 countries and welcomed over two million visitors worldwide. With the iconic all-white dress code and renewed themes every year, Sensation lives up to its name of the ultimate nightlife experience (or: The World’s Leading Dance Event). The Sensation concept has won awards for 'Best Event of the Year' in countries such as The Netherlands, Germany, Australia, Brazil, and Denmark. Sensation utilizes the positive power of music and dance as a universal language, connecting millions of people from around the world.

About Envie Events

Envie Events is proud producer, organizer and promoter of some of the most spectacular, immersive and innovative Dance Music Events in the Middle East including UNITE with Tomorrowland Dubai, Sensation Dubai, I am Hardwell 2016, Armin Only Embrace 2016, Martin Garrix on NYE 2015 and more.

With over 25 years of combined experience in the entertainment, hospitality, and nightlife industry, the company’s events captivate tour senses and inspire a unique level of fan interaction enhanced by state-of-the-art lighting, pyrotechnics and sound design, large-scale art installations and theatrical performers. Having hosted the first world exclusive open-air edition of Sensation in Dubai, two Mega Night Club operations in Europe and various annual partnerships with globally-renowned concepts such as Sensation, Tomorrowland, WMC Miami, and Summer Clubbing Ibiza, Envie Events aspires to become the ultimate destination of choice for events and concerts in Dubai – attracting the entire MENA Region and beyond.

Contacts

Malaika Fernandes

0971 52 954 9333 | Malaika.Fernandes@mediaagency-me.com

Bipin Pathak| Bipin.pathak@mediaagency-me.com



Permalink : http://aetoswire.com/news/4413/en

19 Healthcare Organizations in Taiwan Make Commitments Toward Zero Preventable Patient Deaths

IRVINE, Calif.-Friday, August 25th 2017 [ AETOS Wire ]

(BUSINESS WIRE)-- The Patient Safety Movement Foundation (PSMF) announced today that 19 hospitals and healthcare organizations in Taiwan have signed a commitment to implement processes to eliminate preventable patient deaths. The commitments were announced in Taichung City, Taiwan in June 2017. The Respiratory Therapists Society of the Republic of China also joined the PSMF as a committed partner. These commitments mark a major milestone in the PSMF’s continuing efforts to expand awareness and commitments to action toward protecting patient safety internationally.

The 19 Taiwanese healthcare providers, including some of the country’s top hospitals, have so far made over 20 separate commitments to implement processes such as the PSMF’s Actionable Patient Safety Solutions (APSS). In March 2017, Dr. Chan-Liao became one of the PSMF’s Regional Network Chairs, heading patient safety efforts in Taiwan. He is Chairman of Jen Ai Foundation, Vice President of Jen Ai Hospital and founder of Taiwan Patient Safety Culture Club (TPSCC). He has devoted the past decade to improving patient safety across Taiwan and beyond.

“We are excited to see these commitments from Taiwan. Their commitment to zero preventable deaths is expected to save more than 1,600 lives each year,” said Joe Kiani, Founder of the Patient Safety Movement Foundation. “The movement to protect patients from fatal, unintended harm is an international concern that demands a global effort. Patient Safety is a human right.”

“I am proud of how many of my fellow colleagues across the Taiwanese medical community have stepped up to join me in this effort to reach zero preventable deaths,” said Dr. Chan-Liao Mingi, PSMF’s Regional Network Chair, Chairmen of Jen Ai Foundation, VP of Jen Ai Hospital and founder of TPSCC. “My work with the Patient Safety Movement Foundation has enabled me to expedite our patient safety efforts in Taiwan. I am confident that more and more hospitals will come forward to commit to zero in the coming months. Together, we will save thousands of lives.”

To date, the following 19 hospitals and organizations in Taiwan have committed to one or more APSS. To view each commitment, please visit http://patientsafetymovement.org/challenges-solutions/commitments-pledges/.

Chang Bing Show Chwan Memorial Hospital
   


   


   


   

Kaohsiung Veterans General Hospital

Changhua Christian Hospital
                     

Kuang Tien General Hospital

Cheng Ching General Hospital Chung Kang Branch
                     

Lo-Sheng Sanatorium and Hospital, Ministry of Health and Welfare

Chi Mei Medical Center
                     

Miaoli General Hospital, Ministry of Health and Welfare

Chia-Yi Hospital, Ministry of Health and Welfare
                     

Nantou Hospital Ministry of Health and Welfare

Chung Shan Medical University Hospital
                     

Show Chwan Memorial Hospital

Ditmanson Medical Foundation Chia-Yi Christian Hospital
                     

Taichung Hospital, Ministry of Health and Welfare

E-DA Healthcare Group
                     

Taichung Veterans General Hospital

Feng Yuan Hospital, Ministry of Health and Welfare
                     

Taipei Municipal Wanfang Hospital

Jen Ai Hospital, Dali Branch
                     



About The Patient Safety Movement Foundation

More than 200,000 people die every year in U.S. hospitals and 3 million worldwide in ways that could have been prevented. The Patient Safety Movement Foundation was established through the support of the Masimo Foundation for Ethics, Innovation, and Competition in Healthcare to reduce that number of preventable deaths to 0 by 2020 (0X2020). Improving patient safety will require a collaborative effort from all stakeholders, including patients, healthcare providers, medical technology companies, government, employers, and private payers. The Patient Safety Movement Foundation works with all stakeholders to address the problems with actionable solutions for patient safety. The Foundation also convenes the World Patient Safety, Science & Technology Summit. The Summit brings together some of the world’s best minds for thought-provoking discussions and new ideas to challenge the status quo. By presenting specific, high-impact solutions to meet patient safety challenges, called Actionable Patient Safety Solutions, encouraging medical technology companies to share the data their products are purchased for, and asking hospitals to make commitments to implement Actionable Patient Safety Solutions, the Patient Safety Movement Foundation is working toward zero preventable deaths by 2020. Visit http://patientsafetymovement.org/.

@0X2020 #patientsafety #0X2020

Contacts

Patient Safety Movement Foundation
Irene Mulonni, 858-859-7001
irene@prfordolphins.com


Permalink : http://aetoswire.com/news/4426/en